Continuous Bioprocessing Market

Continuous Bioprocessing Market by Product (Filtration, Chromatography, Centrifuges, Consumables), Application (Commercial {Vaccines, Monoclonal Antibodies}, R&D), End User (Pharmaceuticals, Biotechnology, CROs), and Geography - Forecast to 2027

Report ID: MRHC - 104380
Pages: 200
Mar-2021
Formats*: PDF
Category: Healthcare
Delivery: 2 to 4 Hours

COVID-19

We are in the phase of updating this report by analysing the impact of COVID-19 on this market.

Download sample here

The continuous bioprocessing market is expected to grow at a CAGR of 22.9% from 2020 to 2027 to reach $197.8 million by 2027. Continuous bioprocessing involves manufacturing biopharmaceuticals where continuous unit operations are physically connected with minimal hold volume. Some of the major factors driving the growth of this market include the growing demand for biopharmaceuticals, technological developments in continuous bioprocessing, product launches in the area of continuous bioprocessing, and global initiatives supporting the adoption of biopharmaceuticals. The growing shift towards the bioprocess 4.0 industry, growing opportunities in developing countries, and rising preference for personalized medicine are expected to create significant market growth opportunities.

COVID-19 Impact Assessment

The ongoing global COVID-19 pandemic has diversely impacted healthcare markets either positively or negatively. Various research and development initiatives are being undertaken by several academic institutes and pharma/biopharma manufacturers. Thus, this pandemic is projected to increase demand for cost-effective and modular manufacturing processes, such as continuous bioprocessing.

Pharma manufacturers are investing in vaccine development and production. For instance, in June 2020, the Serum Institute of India announced to invest USD 100 million on the COVID-19 vaccine being developed at Oxford University, in partnership with AstraZeneca Plc. (U.K.), to ensure an equitable supply of the AZD1222 (now commercialized as Covishield) vaccine doses to India and low-and-middle-income countries. In December 2020, a China-based Sinovac Biotech Ltd. received an investment of USD 515 million from local firm Sino Biopharmaceutical to accelerate the production of the COVID-19 vaccine candidate.

As per the Global Vaccine Market Report released by WHO in December 2019, the annual demand for vaccines had reached 3.5 billion doses in 2018. However, with the emergence of COVID-19, this number is expected to reach 9 billion doses of different vaccine modalities by the end of 2021. This sizeable requirement is expected to generate novel approaches like continuous bioprocessing and the use of single-use technologies.

However, the global spread of COVID-19 also adversely impacted operations, sales, and delivery & supply chains. Many countries implemented national lockdowns, shelter-in-place, curfews, travel restrictions, and isolation measures delaying distributions and affecting supply chains of the necessary instruments and consumables, negatively impacting continuous bioprocessing.

Thus, apart from few supply disruptions and operational challenges during the first phase of the pandemic, the overall impact of COVID-19 is expected to be positive on the market with growing pressure from the policymakers to develop novel vaccines and therapies cost-effectively.

Continuous Bioprocessing Market

Click here to: Get Free Sample Pages of this Report

Various initiatives supporting the adoption of biopharmaceuticals is projected to drive the adoption of continuous bioprocessing

The global biosimilars market is fast-growing and possesses strong economic value. Pricing for biosimilars is usually 30-50% lower than that of biologics. This cost advantage gives greater access to biosimilars, further lowering the health expenditure in many countries. As per the Center for Medical Economics and Innovation at the Pacific Research Institute (PRI), U.S., expanding the use of biosimilars to treat serious illnesses like autoimmune diseases or cancer can help reduce the out-of-pocket spending by 17% for the patient.

By the end of 2020, it is projected that near about biologics worth USD 100 billion went off patent, creating opportunities for the biosimilars. The U.S. FDA is expecting the review of over 66 biosimilars as 66 biologics are going off-patent between 2020 and 2025. Knowing the high potential in the biosimilars business, market players such as Mylan N.V (U.S.), Biocon Limited (India), and Aurobindo Pharma Limited (India) are investing in biosimilars. Growing developments in the space of biosimilars are further fueled by supportive initiatives across various countries worldwide.

In February 2020, the U.S. FDA transitioned to a new regulatory pathway to boost the competition between biological products. The U.S. FDA and the Federal Trade Commission (FTC) signed a joint statement regarding enhanced collaboration to support a robust marketplace for biological products like biosimilars and interchangeable products.

China and India are among the leading countries in terms of the development and commercialization of biosimilars. The Chinese government offers multiple initiatives facilitating the development and adoption of biosimilars. The Marketing Authorization Holder (MAH) pilot scheme was launched in China, allowing license holders to sell drugs in China using a contract manufacturer, driving innovations and accelerating the speed at which international companies can introduce products in China, facilitating the growth of CDMOs. Such initiatives are driving the adoption of biosimilars globally, thereby positively impacting the demand for continuous bioprocessing technologies.

Active research in the area of personalized therapies to create several opportunities for market growth

Growing advances in proteomic and genomic sciences have boosted the emergence of personalized therapies. The wave of personalized medicines has entered a mainstream clinical approach, changing the identification, classification, or treatment of diseases. The recognition for personalized medicines is growing among the policymakers, driving the innovative approaches of developing and producing personalized therapies. Continuous bioprocessing and greater accuracy through data analytics and monitoring allow for higher concentrations of next-generation biologics drug dosages, enabling more personalized and effective medicines in potentially smaller/less frequent administration and dosages.

With the pharmaceutical industry moving towards the development of personalized therapies, new manufacturing approaches are being adopted to meet the growing market demand. Advancing continuous bioprocessing has emerged as one of the innovative approaches for manufacturing therapies cost-effectively and on a relatively small scale, offering multiple advantages.

Key Findings in the Global Continuous Bioprocessing Market Study:

In 2020, the filtration systems and consumables segment accounted for the largest share of the market

Based on product, the continuous bioprocessing market is segmented into filtration systems & consumables; chromatography systems & consumables; bioreactors; sterilizers; centrifuges; incubators & shakers; mixing systems; cell culture media, buffers, and reagents; and other products. The growing demand for higher standards of filter operations in biopharma manufacturing is one of the major drivers for the growth of this segment. Filter manufacturers are developing filtration technologies for continuous bioprocessing to achieve both separation and purification through a combination of physical removal capabilities of filtration and size exclusion.

The research & development segment is projected to grow at the highest CAGR during the forecast period

Based on application, the continuous bioprocessing market is segmented into commercial and R&D. The rising focus of R&D to develop vaccines and suitable therapies for COVID-19 and growing relevance of mAb manufacturing for the treatment of various diseases are driving the market growth. The R&D in cell and gene therapy is also accelerated, with over 900 candidates in clinical studies. Facility expansions of CROs or CDMOs to advance research in these areas are expected to boost market growth.

In 2020, the pharmaceutical and biotechnology companies segment dominated the global continuous bioprocessing market

Based on end user, the continuous bioprocessing market is segmented into pharmaceutical and biotechnology companies, CDMOs & CMOs, and academic and research institutes. Pharma and biopharma manufacturers are shifting from batch to continuous processing. This process provides considerable benefits to manufacturers by being more cost-effective, requiring less infrastructure, less space, less investment, less staff, all while manufacturing products in the same or perhaps less time than traditional batch methods.

Asia-Pacific: Fastest growing regional market

Based on region, the market is segmented into North America, Europe, APAC, Latin America, and the Middle East & Africa. The gradually emerging landscape of biopharmaceuticals in Asian countries, CDMO expansions, developments in bioprocessing technologies and partnerships, and collaborations among market players for biopharma manufacturing drives the market growth in Asia-Pacific.

Key Players

The report includes a competitive landscape based on an extensive assessment of the key strategic developments adopted by leading market participants in the industry over the past three years (2018-2021). The key players profiled in the global continuous bioprocessing market report are 3M (U.S.), Cytiva (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), Sartorius AG (Germany), Repligen Corporation (U.S.), Eppendorf AG (Germany), Applikon Biotechnology (Netherlands), Pall Corporation (U.S.), and Bionet (Spain).

Scope of the Report:

Continuous Bioprocessing Market, by Product

Filtration Systems and Consumables
Chromatography Systems and Consumables
Bioreactors
Sterilizers
Centrifuges
Incubators and Shakers
Mixing Systems
Cell Culture Media, Buffers, and Reagents
Other instruments and consumables

Continuous Bioprocessing Market, by Application

Commercial
- Vaccines
- mAb production
- Recombinant Protein Production
- Cell and Gene Therapy Production
R&D

Continuous Bioprocessing Market, by End User

Pharmaceutical and Biotechnology Companies
Contract Development and Manufacturing Organizations and Contract Research Organizations
Academic and Research Institutes

Continuous Bioprocessing Market, by Geography

North America
- U.S.
- Canada
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe (RoE)
Asia-Pacific (APAC)
- China
- Japan
- India
- Rest of APAC (RoAPAC)
Latin America
Middle East & Africa

Key questions answered in the report:

What is the focus of the global continuous bioprocessing market?

The global continuous bioprocessing market covers the market size & forecasts of continuous bioprocessing products like filtration systems & consumables; chromatography systems & consumables; bioreactors; sterilizers; centrifuges; incubators/shakers; mixing systems and cell culture media, reagents, and buffers; and other instruments and consumables.

What is the value of revenue generated from continuous bioprocessing across the globe? At what rate is their demand expected to grow for the next 5-7 years?

The global continuous bioprocessing market is projected to reach $197.8 million by 2027, at a CAGR of 22.9% during the forecast period.

Which continuous bioprocessing product is estimated to hold the major share of the market?

Based on product, the filtration systems and consumables commanded the largest share of the market in 2020.

Which application segment is expected to grow at the highest CAGR during the forecast period?

Based on application, the continuous bioprocessing market is segmented into commercial and R&D. The R&D segment is expected to grow at the highest CAGR.

Which end-user segment accounted for the largest share of the continuous bioprocessing market?

In 2020, the pharmaceutical and biotechnology companies segment accounted for the largest share of the market.

What are the key factors supporting the growth of this market? What are the major opportunities for existing market players and new entrants in the global continuous bioprocessing market?

Some of the major factors driving the growth of this market include the growing demand for biopharmaceuticals, technological developments in continuous bioprocessing, product launches in the area of continuous bioprocessing, and global initiatives supporting the adoption of biopharmaceuticals. The growing shift towards the bioprocess 4.0 industry, growing opportunities in developing countries, and rising preference for personalized medicine are expected to create significant market growth opportunities.

Who are the major players operating in the global continuous bioprocessing market?

The key players profiled in the global continuous bioprocessing market are 3M (U.S.), Cytiva (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), Sartorius AG (Germany), Repligen Corporation (U.S.), Eppendorf AG (Germany), Applikon Biotechnology (Netherlands), Pall Corporation (U.S.), and Bionet (Spain)

Which regions/countries are expected to offer significant growth opportunities for the vendors operating in the continuous bioprocessing market?

Emerging economies like China and India are projected to offer significant growth opportunities for vendors in this market.

Download Sample

1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders

2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-Up Approach
2.3.1.2. Top-Down Approach
2.3.1.3. Growth Forecast
2.3.2. Market Share Analysis
2.4. Assumptions for this Study
2.5. Limitations for the Study

3. Executive Summary

4. Market Insights
4.1. Introduction
4.2. Drivers
4.2.1. Growing Adoption of Continuous Manufacturing
4.2.2. Global Initiatives Supporting the Adoption of Biopharmaceuticals
4.2.3. Advantages of Continuous Bioprocessing
4.3. Restraints
4.3.1. Complex Procedure
4.4. Opportunities
4.4.1. Growing Shift Towards Bioprocess 4.0 Industry
4.4.2 Developing Countries
4.5. Challenges
4.5.1. Reluctance of Manufacturers to Shift from Batch Manufacturing
4.6 Market Trends
4.6.1 Growth in the Use of Single-use Technologies in Bioprocessing
4.7. The Impact of COVID-19 on the Continuous Bioprocessing Market

5. Global Continuous Bioprocessing Market, by Product
5.1 Introduction
5.2 Filtration Systems and Consumables
5.3 Chromatography Systems and Consumables
5.4 Bioreactors
5.5 Sterilizers
5.6 Centrifuges
5.7 Incubators and Shakers
5.8 Mixing Systems
5.9 Cell Culture Media, Buffers and Reagents
5.10 Other Instruments and Consumables

6. Global Continuous Bioprocessing Market, by Application
6.1. Introduction
6.2 Commercial
6.2.1 Vaccines
6.2.2 mAb Production
6.2.3 Recombinant Protein Production
6.2.4 Cell and Gene Therapy Production
6.3 R&D

7 Global Continuous Bioprocessing Market, by End User
7.1 Pharmaceutical and Biotechnology Companies
7.2 Contract Development and Manufacturing Organizations and Contract Research Organization
7.3 Academic and Research Institutes

8 Global Continuous Bioprocessing Market, by Geography
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. U.K.
8.3.4. Italy
8.3.5. Spain
8.3.6. Rest of Europe (RoE)
8.4. Asia-Pacific
8.4.1. Japan
8.4.2. China
8.4.3. India
8.4.4. Rest of Asia-Pacific (RoAPAC)
8.5. Latin America
8.6. Middle East & Africa

9 Competitive Landscape
9.1. Introduction
9.2. Key Growth Strategies
9.3. Competitive Benchmarking
9.4. Market Share Analysis (2019)

10 Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments)
10.1. 3M Company (U.S.)
10.2. Cytiva (U.S.)
10.3. Thermo Fisher Scientific, Inc. (U.S.)
10.4. Merck KGaA (Germany)
10.5. Sartorius AG (Germany)
10.6. Repligen Corporation (U.S.)
10.7. Eppendorf AG (Germany)
10.8. Applikon Biotechnology (The Netherlands)
10.9. Pall Corporation (U.S.)
10.10. Bionet (Spain)

11 Appendix
11.1. Questionnaire
11.2. Available Customization

List of Tables

Table 1 Global Continuous Bioprocessing Market Drivers: Impact Analysis
Table 2 Global Continuous Bioprocessing Market Restraints: Impact Analysis
Table 3 Global Continuous Bioprocessing Market Size, by Product, 2018–2027, (USD Million)
Table 4 Global Filtration Systems and Consumables Size, by Country/Region, 2018–2027, (USD Million)
Table 5 Global Chromatography Systems and consumables Market Size, by Country/Region, 2018–2027, (USD Million)
Table 6 Global Bioreactors Market Size, by Country/Region, 2018–2027, (USD Million)
Table 7 Global Sterilizers Market Size, by Country/Region, 2018–2027, (USD Million)
Table 8 Global Centrifuges Market Size, by Country/Region, 2018–2027, (USD Million)
Table 9 Global Incubators/Shakers Market Size, by Country/Region, 2018–2027, (USD Million)
Table 10 Global Mixing Systems Market Size, by Country/Region, 2018–2027, (USD Million)
Table 11 Global Cell Culture Media, Buffers and Reagents Market Size, by Country/Region, 2018–2027, (USD Million)
Table 12 Global Other Instruments and Consumables Market Size, by Country/Region, 2018–2027, (USD Million)
Table 13 Global Continuous Bioprocessing Market Size, by Application, 2018–2027 (USD Million)
Table 14 Global Continuous Bioprocessing Market Size for Commercial Applications, by Type, 2018–2027 (USD Million)
Table 15 Global Continuous Bioprocessing Market Size for Commercial Applications, by Country/Region, 2018–2027 (USD Million)
Table 16 Global Continuous Bioprocessing Market Size for Vaccine Manufacturing, by Country/Region, 2018–2027 (USD Million)
Table 17 Global Continuous Bioprocessing Market Size for mAb Manufacturing, by Country/Region, 2018–2027 (USD Million)
Table 18 Global Continuous Bioprocessing Market Size for Recombinant Protein Manufacturing, by Country/Region, 2018–2027 (USD Million)
Table 19 Global Continuous Bioprocessing Market Size for Cell and Gene Therapy Manufacturing, by Country/Region, 2018–2027 (USD Million)
Table 20 Global Continuous Bioprocessing Market Size for R&D Applications, by Country/Region, 2018–2027 (USD Million)
Table 21 Global Continuous Bioprocessing Market Size, by End User, 2018–2027 (USD Million)
Table 22 Global Continuous Bioprocessing Market Size for Pharmaceutical and Biotechnology Companies, by Country/Region, 2018–2027 (USD Million)
Table 23 Global Continuous Bioprocessing Market Size for Contract Development and Manufacturing Organizations and Contract Research Organization, by Country/Region, 2018–2027 (USD Million)
Table 24 Global Continuous Bioprocessing Market Size for Academic and Research Institutes, by Country/Region, 2018–2027 (USD Million)
Table 25 Global Continuous Bioprocessing Market Size, by Country/ Region, 2018–2027, (USD Million)
Table 26 North America: Continuous Bioprocessing Market Size, by Country, 2018–2027, (USD Million)
Table 27 North America: Continuous Bioprocessing Market Size, by Product, 2018–2027, (USD Million)
Table 28 North America: Continuous Bioprocessing Market Size, by Application, 2018–2027, (USD Million)
Table 29 North America: Continuous Bioprocessing Market Size for Commercial Applications, by Type, 2018–2027, (USD Million)
Table 30 North America: Continuous Bioprocessing Market Size, by End User, 2018–2027, (USD Million)
Table 31 U.S.: Continuous Bioprocessing Market Size, by Product, 2018–2027, (USD Million)
Table 32 U.S.: Continuous Bioprocessing Market Size, by Application, 2018–2027, (USD Million)
Table 33 U.S: Continuous Bioprocessing Market Size for Commercial Applications, by Type, 2018–2027, (USD Million)
Table 34 U.S.: Continuous Bioprocessing Market Size, by End User, 2018–2027, (USD Million)
Table 35 Canada: Continuous Bioprocessing Market Size, by Product, 2018–2027, (USD Million)
Table 36 Canada: Continuous Bioprocessing Market Size, by Application, 2018–2027, (USD Million)
Table 37 Canada: Continuous Bioprocessing Market Size for Commercial Applications, by Type, 2018–2027, (USD Million)
Table 38 Canada: Continuous Bioprocessing Market Size, by End User, 2018–2027, (USD Million)
Table 39 Europe: Continuous Bioprocessing Market Size, by Country, 2018–2027, (USD Million)
Table 40 Europe: Continuous Bioprocessing Market Size, by Product, 2018–2027, (USD Million)
Table 41 Europe: Continuous Bioprocessing Market Size, by Application, 2018–2027, (USD Million)
Table 42 Europe: Continuous Bioprocessing Market Size for Commercial Applications, by Type, 2018–2027, (USD Million)
Table 43 Europe: Continuous Bioprocessing Market Size, by End User, 2018–2027, (USD Million)
Table 44 U.K.: Continuous Bioprocessing Market Size, by Product, 2018–2027, (USD Million)
Table 45 U.K.: Continuous Bioprocessing Market Size, by Application, 2018–2027, (USD Million)
Table 46 U.K.: Continuous Bioprocessing Market Size for Commercial Applications, by Type, 2018–2027, (USD Million)
Table 47 U.K.: Continuous Bioprocessing Market Size, by End User, 2018–2027, (USD Million)
Table 48 Germany: Continuous Bioprocessing Market Size, by Product, 2018–2027, (USD Million)
Table 49 Germany: Continuous Bioprocessing Market Size, by Application, 2018–2027, (USD Million)
Table 50 Germany: Continuous Bioprocessing Market Size for Commercial Applications, by Type, 2018–2027, (USD Million)
Table 51 Germany: Continuous Bioprocessing Market Size, by End User, 2018–2027, (USD Million)
Table 52 France: Continuous Bioprocessing Market Size, by Product, 2018–2027, (USD Million)
Table 53 France: Continuous Bioprocessing Market Size, by Application, 2018–2027, (USD Million)
Table 54 France: Continuous Bioprocessing Market Size for Commercial Applications, by Type, 2018–2027, (USD Million)
Table 55 France: Continuous Bioprocessing Market Size, by End User, 2018–2027, (USD Million)
Table 56 Spain: Continuous Bioprocessing Market Size, by Product, 2018–2027, (USD Million)
Table 57 Spain: Continuous Bioprocessing Market Size, by Application, 2018–2027, (USD Million)
Table 58 Spain: Continuous Bioprocessing Market Size for Commercial Applications, by Type, 2018–2027, (USD Million)
Table 59 Spain: Continuous Bioprocessing Market Size, by End User, 2018–2027, (USD Million)
Table 60 Italy: Continuous Bioprocessing Market Size, by Product, 2018–2027, (USD Million)
Table 61 Italy: Continuous Bioprocessing Market Size, by Application, 2018–2027, (USD Million)
Table 62 Italy: Continuous Bioprocessing Market Size for Commercial Applications, by Type, 2018–2027, (USD Million)
Table 63 Italy: Continuous Bioprocessing Market Size, by End User, 2018–2027, (USD Million)
Table 64 Rest of Europe: Continuous Bioprocessing Market Size, by Product, 2018–2027, (USD Million)
Table 65 Rest of Europe: Continuous Bioprocessing Market Size, by Application, 2018–2027, (USD Million)
Table 66 Rest of Europe: Continuous Bioprocessing Market Size for Commercial Applications, by Type, 2018–2027, (USD Million)
Table 67 Rest of Europe: Continuous Bioprocessing Market Size, by End User, 2018–2027, (USD Million)
Table 68 Asia-Pacific: Continuous Bioprocessing Market Size, by Country, 2018–2027, (USD Million)
Table 69 Asia-Pacific: Continuous Bioprocessing Market Size, by Product, 2018–2027, (USD Million)
Table 70 Asia-Pacific: Continuous Bioprocessing Market Size, by Application, 2018–2027, (USD Million)
Table 71 Asia-Pacific: Continuous Bioprocessing Market Size for Commercial Applications, by Type, 2018–2027, (USD Million)
Table 72 Asia-Pacific: Continuous Bioprocessing Market Size, by End User, 2018–2027, (USD Million)
Table 73 China: Continuous Bioprocessing Market Size, by Product, 2018–2027, (USD Million)
Table 74 China: Continuous Bioprocessing Market Size, by Application, 2018–2027, (USD Million)
Table 75 China: Continuous Bioprocessing Market Size for Commercial Applications, by Type, 2018–2027, (USD Million)
Table 76 China: Continuous Bioprocessing Market Size, by End User, 2018–2027, (USD Million)
Table 77 Japan: Continuous Bioprocessing Market Size, by Product, 2018–2027, (USD Million)
Table 78 Japan: Continuous Bioprocessing Market Size, by Application, 2018–2027, (USD Million)
Table 79 Japan: Continuous Bioprocessing Market Size for Commercial Applications, by Type, 2018–2027, (USD Million)
Table 80 Japan: Continuous Bioprocessing Market Size, by End User, 2018–2027, (USD Million)
Table 81 India: Continuous Bioprocessing Market Size, by Product, 2018–2027, (USD Million)
Table 82 India: Continuous Bioprocessing Market Size, by Application, 2018–2027, (USD Million)
Table 83 India: Continuous Bioprocessing Market Size for Commercial Applications, by Type, 2018–2027, (USD Million)
Table 84 India: Continuous Bioprocessing Market Size, by End User, 2018–2027, (USD Million)
Table 85 Rest of Asia-Pacific: Continuous Bioprocessing Market Size, by Product, 2018–2027, (USD Million)
Table 86 Rest of Asia-Pacific: Continuous Bioprocessing Market Size, by Application, 2018–2027, (USD Million)
Table 87 Rest of Asia-Pacific: Continuous Bioprocessing Market Size for Commercial Applications, by Type, 2018–2027, (USD Million)
Table 88 Rest of Asia-Pacific: Continuous Bioprocessing Market Size, by End User, 2018–2027, (USD Million)
Table 89 Latin America: Continuous Bioprocessing Market Size, by Product, 2018–2027, (USD Million)
Table 90 Latin America: Continuous Bioprocessing Market Size, by Application, 2018–2027, (USD Million)
Table 91 Latin America: Continuous Bioprocessing Market Size for Commercial Applications, by Type, 2018–2027, (USD Million)
Table 92 Latin America: Continuous Bioprocessing Market Size, by End User, 2018–2027, (USD Million)
Table 93 Middle East and Africa: Continuous Bioprocessing Market Size, by Product, 2018–2027, (USD Million)
Table 94 Middle East and Africa: Continuous Bioprocessing Market Size, by Application, 2018–2027, (USD Million)
Table 95 Middle East and Africa: Continuous Bioprocessing Market Size for Commercial Applications, by Type, 2018–2027, (USD Million)
Table 96 Middle East and Africa: Continuous Bioprocessing Market Size, by End User, 2018–2027, (USD Million)
Table 97 Recent Developments, by Company, 2018-2021

List of Figures

Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives interviewed
Figure 5 Breakdown of Primary interviews (Supply-Side & Demand-Side)
Figure 6 Market Size Estimation
Figure 7 Global Continuous Bioprocessing Market Size, by Product, 2020–2027 (USD Million)
Figure 8 Global Continuous Bioprocessing Market Size, by Application, 2020–2027 (USD Million)
Figure 9 Global Continuous Bioprocessing Market Size, by End User (2020–2027) (USD Million)
Figure 10 Global Continuous Bioprocessing Market, by Region (USD Million)
Figure 11 Market Dynamics
Figure 12 Global Continuous Bioprocessing Market Size, by Product, 2020–2027 (USD Million)
Figure 13 Global Continuous Bioprocessing Market Size, by Application, 2020–2027 (USD Million)
Figure 14 Global Continuous Bioprocessing Market Size, by End User, 2020–2027 (USD Million)
Figure 15 Global Continuous Bioprocessing Market Size, by Region, 2020–2027 (USD Million)
Figure 16 Geographic Snapshot: North American Continuous Bioprocessing Market
Figure 17 Geographic Snapshot: European Continuous Bioprocessing Market
Figure 18 Geographic Snapshot: Asia-Pacific Continuous Bioprocessing Market
Figure 19 Key Growth Strategies Adopted by Leading Players, 2018-2021
Figure 20 Continuous Bioprocessing: Competitive Benchmarking by Product
Figure 21 Continuous Bioprocessing: Competitive Benchmarking by Geography
Figure 22 Market Share Analysis: Continuous Bioprocessing Industry, 2019
Figure 23 3M.: Financial Snapshot (2020)
Figure 24 Cytiva: Financial Snapshot (2020)
Figure 25 Thermo Fisher Scientific, Inc.: Financial Snapshot (2020)
Figure 26 Merck KGaA: Financial Snapshot (2020)
Figure 27 Sartorius AG: Financial Snapshot (2020)
Figure 28 Repligen Corporation: Financial Snapshot (2020)
Figure 29 Eppendorf AG: Financial Snapshot (2020)
Figure 30 Applikon Biotechnology (Netherlands).: Financial Snapshot (2020)
Figure 31 Pall Corporation (U.S.): Financial Snapshot (2020)
Figure 32 Bionet (Spain).: Financial Snapshot (2020)

Download Sample

Full Name:

Name can only consist of alphabets.

Please provide your full name.

Email:

Please provide valid email address.

Please provide your email address.

Job Title:

Please provide your job title.

Company:

Please provide your company name.

City:

Please provide your company name.

Phone Number

Please provide valid phone number.

Please provide your phone number.

Specific Interest

Please enter minimum 10 characters.

Captcha:

Please enter Captcha.

Please enter valid Captcha.

This website is secure and we do not share your personal information with any third party. Privacy Policy

SELECT PDF LICENSE

Single User 10% Discount

$ 3757.5 ~~$ 4175.00~~ With the help of Single User License, only an individual can use our report either electronically or online. The right to use of the report should be confined only to one authorized computer. Upon buying single user license, buyer must provide the names and email ids of the authorized users of this report.

Multiple Users 15% Discount

$ 4993.75 ~~$ 5875.00~~
Multi-User license permits to access the report from five authorized computers. It does not permit you to share the report with other divisions and subsidiaries of the same company. Upon buying multi-user license, buyer must provide the names and email ids of the authorized users of this report. (Recommended)

Corporate User 20% Discount

$ 5980 ~~$ 7475.00~~ With corporate use license, the complete or part of the content of the report can be shared or made available to other persons, other divisions and subsidiaries of same company. However, reproduction or redistribution of the report is prohibited without the prior permission of Meticulous Research.

Enquire

Check Discount

Request Sample

Speak to Analyst